BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

739 related articles for article (PubMed ID: 14759453)

  • 1. Effects of nafamostat mesilate and minimal-dose aprotinin on blood-foreign surface interactions in cardiopulmonary bypass.
    Kaminishi Y; Hiramatsu Y; Watanabe Y; Yoshimura Y; Sakakibara Y
    Ann Thorac Surg; 2004 Feb; 77(2):644-50. PubMed ID: 14759453
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nafamostat mesilate reduces blood-foreign surface reactions similar to biocompatible materials.
    Usui A; Hiroura M; Kawamura M; Hibi M; Yoshida K; Murakami F; Tomita Y; Ooshima H; Murase M
    Ann Thorac Surg; 1996 Nov; 62(5):1404-11. PubMed ID: 8893576
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hemostatic activation during cardiopulmonary bypass with different aprotinin dosages in pediatric patients having cardiac operations.
    Dietrich W; Mössinger H; Spannagl M; Jochum M; Wendt P; Barankay A; Meisner H; Richter JA
    J Thorac Cardiovasc Surg; 1993 Apr; 105(4):712-20. PubMed ID: 7682267
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aprotinin reduces blood loss after cardiopulmonary bypass by direct inhibition of plasmin.
    Ray MJ; Marsh NA
    Thromb Haemost; 1997 Sep; 78(3):1021-6. PubMed ID: 9308747
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of two different doses of aprotinin on hemostasis in cardiopulmonary bypass surgery: similar transfusion requirements and blood loss.
    Santamaría A; Mateo J; Oliver A; Litvan H; Murillo J; Souto JC; Fontcuberta J
    Haematologica; 2000 Dec; 85(12):1277-84. PubMed ID: 11114135
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nafamostat mesilate, a broad spectrum protease inhibitor, modulates platelet, neutrophil and contact activation in simulated extracorporeal circulation.
    Sundaram S; Gikakis N; Hack CE; Niewiarowski S; Edmunds LH; Koneti Rao A; Sun L; Cooper SL; Colman RW
    Thromb Haemost; 1996 Jan; 75(1):76-82. PubMed ID: 8713783
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Coagulation and fibrinolysis system in aortic surgery under deep hypothermic circulatory arrest with aprotinin: the importance of adequate heparinization.
    Okita Y; Takamoto S; Ando M; Morota T; Yamaki F; Matsukawa R; Kawashima Y
    Circulation; 1997 Nov; 96(9 Suppl):II-376-81. PubMed ID: 9386127
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aprotinin inhibits the contact, neutrophil, and platelet activation systems during simulated extracorporeal perfusion.
    Wachtfogel YT; Kucich U; Hack CE; Gluszko P; Niewiarowski S; Colman RW; Edmunds LH
    J Thorac Cardiovasc Surg; 1993 Jul; 106(1):1-9; discussion 9-10. PubMed ID: 7686593
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Surface-bound heparin fails to reduce thrombin formation during clinical cardiopulmonary bypass.
    Gorman RC; Ziats N; Rao AK; Gikakis N; Sun L; Khan MM; Stenach N; Sapatnekar S; Chouhan V; Gorman JH; Niewiarowski S; Colman RW; Anderson JM; Edmunds LH
    J Thorac Cardiovasc Surg; 1996 Jan; 111(1):1-11; discussion 11-2. PubMed ID: 8551753
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is use of aprotinin safe with deep hypothermic circulatory arrest in aortic surgery? Investigations on blood coagulation.
    Okita Y; Takamoto S; Ando M; Morota T; Yamaki F; Kawashima Y
    Circulation; 1996 Nov; 94(9 Suppl):II177-81. PubMed ID: 8901742
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nafamostat mesilate reduces blood loss during open heart surgery.
    Murase M; Usui A; Tomita Y; Maeda M; Koyama T; Abe T
    Circulation; 1993 Nov; 88(5 Pt 2):II432-6. PubMed ID: 8222190
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Postoperative hemostasis and fibrinolysis in patients undergoing cardiopulmonary bypass with or without aprotinin therapy.
    Lu H; Du Buit C; Soria J; Touchot B; Chollet B; Commin PL; Conseiller C; Echter E; Soria C
    Thromb Haemost; 1994 Sep; 72(3):438-43. PubMed ID: 7531877
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low doses of aprotinin in aortocoronary bypass surgery--advantages and disadvantages.
    Golański R; Golański J; Chizyński K; Iwaszkiewicz A; Zasłonka J; Pietrucha T; Chrul S; Watała C
    Med Sci Monit; 2000; 6(4):722-8. PubMed ID: 11208399
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is reduced systemic heparinization justified with heparin-bonded bypass circuits in cardiac surgery?--Experience with and without aprotinin.
    Kipfer B; Englberger L; Gygax E; Nydegger U; Carrel T
    Transfus Apher Sci; 2003 Aug; 29(1):17-24. PubMed ID: 12877888
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of high-dose aprotinin on blood loss, platelet function, fibrinolysis, complement, and renal function after cardiopulmonary bypass.
    Blauhut B; Gross C; Necek S; Doran JE; Späth P; Lundsgaard-Hansen P
    J Thorac Cardiovasc Surg; 1991 Jun; 101(6):958-67. PubMed ID: 1710008
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of nafamostat mesilate on platelets and coagulofibrinolysis during cardiopulmonary bypass surgery.
    Tanaka K; Kondo C; Takagi K; Sato T; Yada I; Yuasa H; Kusagawa M
    ASAIO J; 1993; 39(3):M545-9. PubMed ID: 8268595
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nafamostat preserves neutrophil deformability and reduces microaggregate formation during simulated extracorporeal circulation.
    Hiramatsu Y; Homma S; Sato Y; Sato S; Matsuzaki K; Shigeta O; Sakakibara Y
    Ann Thorac Surg; 2005 Apr; 79(4):1326-32. PubMed ID: 15797071
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Heparin-level-based anticoagulation management during cardiopulmonary bypass: a pilot investigation on the effects of a half-dose aprotinin protocol on postoperative blood loss and hemostatic activation and inflammatory response.
    Koster A; Huebler S; Merkle F; Hentschel T; Gründel M; Krabatsch T; Tambeur L; Praus M; Habazettl H; Kuebler WM; Kuppe H
    Anesth Analg; 2004 Feb; 98(2):285-290. PubMed ID: 14742356
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Coagulation-fibrinolysis changes during off-pump bypass: effect of two heparin doses.
    Paparella D; Semeraro F; Scrascia G; Galeone A; Ammollo CT; Kounakis G; de Luca Tupputi Schinosa L; Semeraro N; Colucci M
    Ann Thorac Surg; 2010 Feb; 89(2):421-7. PubMed ID: 20103314
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nafamostat mesilate, as a treatment for heparin resistance, is not associated with perioperative ischemic stroke in patients undergoing cardiac surgery with cardiopulmonary bypass.
    Kikura M; Tanaka K; Hiraiwa T; Tanaka K
    J Cardiothorac Vasc Anesth; 2012 Apr; 26(2):239-44. PubMed ID: 22019206
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.